[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-disease":23},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,473,0,25,[9,39,72,98,122,147,184,208,230,254,280,300,325,352,377,397,418,436,465,473,503,526,551,572,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054277","deep-brain-stimulation-dbs-retrospective-outcomes-study-100054277",false,"NCT03664609","Deep Brain Stimulation (DBS) Retrospective Outcomes Study","Inclusion Criteria:\n\n* Must be previously treated with or eligible for implantation with a deep brain stimulation system\n\nExclusion Criteria:\n\n* No Exclusion Criteria","ALL",{"count":18,"type":19},5000,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.",[23,24,25],"Parkinson Disease","Essential Tremor","Dystonia","RECRUITING","2026-07-10",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2019-03-12",{"date":34,"type":19},"2028-12",{"name":36,"class":37},"Boston Scientific Corporation","INDUSTRY",19,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100054002","virtual-cycling-environments-for-persons-with-parkinson-disease-100054002","NCT04804202","Virtual Cycling Environments for Persons With Parkinson Disease","Virtual Cycling Environments (VCYCLE) Increases Exercise Intensity of Persons With Parkinson Disease","VCYCLE_PD","Inclusion Criteria:\n\n1. Diagnosis of Parkinson's disease\n2. Hoehn and Yahr stages II-III,\n3. 45-75 years old\n4. able to ride a stationary upright bicycle\n5. able to sign informed consent.\n\nExclusion Criteria:\n\n1. Have a recent history of severe heart disease, severe lung disease, uncontrolled diabetes, traumatic brain injury or neurological disorder other than Parkinson Disease.\n2. Are unable to follow directions or sign a consent form\n3. Do not have adequate vision or hearing ability to see or hear a television\n4. Have unstable medical condition or musculoskeletal disorder such as severe arthritis, recent knee surgery, hip surgery, or any other condition that the investigators determine would impair the ability to ride the bicycle\n5. Have any other medical condition that prevents bicycling\n6. Have moderate depression","45 Years","75 Years",{"count":50,"type":19},60,"INTERVENTIONAL",[53],"NA","This study asks three questions about Persons with Parkinson Disease that use a bicycle for exercise. 1. Does the use of virtual reality increase the intensity and and enjoyment of the experience compared to bicycling without virtual reality? 2. Does the way in which the bicycling (interval compared to continous) is performed affect the experience? 3. How does the way the virtual reality is delivered (with goggles or projected on a screen) affect the experience?",[23],[57,58,59,60,61],"virtual reality","exercise","cardiovascular intensity","neuromuscular intensity","enjoyment","2026-07-09",{"date":29,"type":30},{"date":65,"type":30},"2021-02-08",{"date":67,"type":19},"2027-12-30",{"name":69,"class":70},"Rutgers, The State University of New Jersey","OTHER",2,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100429766","sonification-techniques-for-gait-training-100429766","NCT04876339","Sonification Techniques for Gait Training","Sonification Techniques for Gait Training: a Pilot Multicentric Randomized Controlled Trial","SonicWalk","Inclusion criteria (stroke patients)\n\n* Age \\\u003C 80\n* Mini Mental State Examination \\> 24\n* Modified Rankin Scale: 1-3\n* Single hemisphere lesion\n* Stabilized disease (\\> 6 months after the acute event)\n* Impairment in gait parameters (e.g. velocity, perceived fatigue etc)\n* Motor independence during walking (without orthotic devices and aids) but with pathological pattern (spasticity level: Ashworth \\\u003C 2)\n\nInclusion criteria (patients with Parkinson's disease)\n\n* Age \\\u003C 80\n* Mini Mental State Examination \\> 24\n* Unified Parkinson Disease Rating Scale score (Parte III): \\\u003C 28\n* Stabilized disease and drug therapy\n* Altered gait patterns\n* Motor independence during walking (without orthotic devices and aids) but with pathological pattern\n\nInclusion criteria (patients with multiple sclerosis):\n\n* Age \\\u003C 60\n* Mini Mental State Examination \\> 24\n* Expanded Disability Status Scale score: 3-5\n* Stabilized disease in the last 6 months (without relapse or disability progression)\n* Altered gait patterns (i.e., careening, slowing down, spasticity: Ashworth \\\u003C 2, etc.)\n* Motor independence during walking\n\nExclusion Criteria (stroke patients)\n\n* Multiple or bilateral lesions\n* Neglect\n* Equinism\n* Spasticity: Ashworth \\>2\n* Structured (non-elastic) Achilles tendon retraction\n* Neurotoxin in the 3 months prior to the study\n* Baclofen introduced or modified in the week before the start of the study\n* Previous or concurrent diseases disabling the lower limb functions\n* Rehabilitative treatments with music in the year before the study\n\nExclusion criteria (patients with Parkinson's disease):\n\n* Previous or concurrent diseases disabling the lower limb functions\n* Changes of drug therapy during the study\n* Rehabilitative treatments with music in the year before the study\n\nExclusion criteria (patients with multiple sclerosis):\n\n* Previous or concurrent diseases disabling the lower limb functions\n* Neurotoxin in the 3 months prior to the study\n* Baclofen introduced or modified in the week before the start of the study\n* Spasticity: Ashworth \\>2\n* Structured (non-elastic) Achilles tendon retraction\n* Rehabilitative treatments with music in the year before the study","80 Years",{"count":82,"type":19},120,[53],"Music therapy is widely used in relational and rehabilitation settings. In addition to Neurologic Music Therapy and other music-based techniques, \"sonification\" approaches were recently introduced in the field of rehabilitation. The \"sonification\" can be defined as a properly selected set of sonorous-music stimuli are associated with patient movements mapping. In fact, the auditory-motor feedback can replace damaged proprioceptive circuits with a consequent improvement of the rehabilitation process. Interventions with \"sonification\" facilitate sensorimotor learning, proprioception and movements planning and execution improving global motor parameters. This study proposes the use of musical auditory cues which includes the melodic-harmonic component of the music. This kind of sonification makes the feedback pleasant and predictable as well as potentially effective. The investigators propose to apply and assess the effectiveness of this kind of sonification on gait training and other secondary outcomes in stroke, Parkinson's disease and multiple sclerosis population. Also, the investigators will assess the impact of \"sonification\" on the level of fatigue perceived during the rehabilitation process and on the quality of life. The study is a multicenter randomized controlled trial and will involve 120 patients that will undergo standard motor rehabilitation or the same rehabilitation but with the sonification support. The interventions will be evaluated at the baseline, after 10 sessions, after 20 sessions and at follow-up (one month after the end of the treatment). The assessment will include functional, motor, fatigue and quality of life evaluations. The collected data will be statistically processed.",[23,86,87],"Stroke","Multiple Sclerosis","2026-07-01",{"date":90,"type":30},"2026-07-02",{"date":92,"type":30},"2021-01-18",{"date":94,"type":19},"2027-06-30",{"name":96,"class":70},"Istituti Clinici Scientifici Maugeri SpA",1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":47,"maxAge":80,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":97},"100551741","pathways-mediating-impaired-postural-control-in-parkinsons-disease-100551741","NCT06464029","Pathways Mediating Impaired Postural Control in Parkinson's Disease","Inclusion Criteria:\n\nParticipants with Parkinson's disease\n\n* Diagnosis of idiopathic PD or dystonia as determined by a movement disorders neurologist in accordance with the UK Society Brain Bank diagnostic criteria.\n* Age 45-80 years.\n* Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters.\n\nHealthy Older Adults (Control participants)\n\n* Age 45-80 years (this group will be age and sex-matched to the PD group)\n* Able to ambulate independently without the use of an assistive device (cane or walker)\n\nHealthy Young Adults\n\n* Age 21-44 years (this group will be age and sex-matched to the PD group)\n* Able to ambulate independently without the use of an assistive device (cane or walker)\n\nExclusion Criteria:\n\n* Subjects who describe a history of a frequent vasovagal syncope (fainting) in response to blood, emotional stress, or sensory triggers.\n* Subjects who are on anti-coagulant medications.\n* Any musculoskeletal disorder that affects the ability to stand.\n* History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury.\n* Intracranial metallic or magnetic devices.\n* Pacemaker or any implanted device.\n* History of surgery on blood vessels, brain or heart.\n* Unexplained, recurring headaches or concussion within the last six months.\n* Moderate to severe hearing impairment.\n* Subjects who are pregnant.\n* Dementia diagnosis\n* Other significant neurological disorders that may affect participation or performance in the study\n* Implanted deep brain stimulator or other neurosurgeries to treat PD.",true,{"count":106,"type":19},160,"The purpose of this project is to use transcranial magnetic stimulation (TMS) to explore the state of excitability of corticocortical and corticofugal (cortex to spinal cord, cortex to brainstem to spinal cord) pathways that project to muscles that control the legs and trunk in people with Parkinson's disease. The outcome variables will be further analyzed to understand their relationship to quantitative measures of postural instability and gait dysfunction. As such, the project can be classified as basic physiologic research. The protocol is not designed to determine if measures of corticocortical or corticofugal excitability can be used as a biomarker to predict disease progression.",[23],[110,111,112,113],"gait","posture","transcranial magnetic stimulation","Parkinson's disease","2026-06-30",{"date":90,"type":30},{"date":117,"type":30},"2024-06-01",{"date":119,"type":19},"2027-06-10",{"name":121,"class":70},"University of Minnesota",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":16,"minAge":129,"maxAge":80,"enrollmentInfo":130,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":97},"100637658","a-long-term-follow-up-study-of-the-severe-parkinsons-disease-patients-administered-the-ips101a-gene-therapy-product-100637658","NCT07629115","A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.","A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial","Inclusion Criteria\n\n* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.\n* Subjects and\u002For their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.\n\nExclusion Criteria\n\n* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.\n* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.","50 Years",{"count":131,"type":19},6,"The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.",[23,134],"Parkinson's Disease",[136,137,138],"Adeno-associated Virus","Gene therapy","AAV","2026-06-29",{"date":88,"type":30},{"date":142,"type":30},"2026-05-29",{"date":144,"type":19},"2031-10-30",{"name":146,"class":37},"Innopeutics Corporation",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":80,"enrollmentInfo":156,"targetDuration":4,"studyType":51,"phases":158,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100568408","phase-2-a-phase-2-study-and-open-label-extension-of-neu-411-in-companion-diagnostic-positive-participants-with-early-parkinsons-disease-100568408","NCT06680830","A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)","NEULARK","Inclusion Criteria:\n\n1. Aged 40-80 years at time of screening, inclusive\n2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)\n3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx)\n4. Modified Hoehn and Yahr (mH\\&Y) of 1 to 2.5\n\nExclusion Criteria:\n\n1. Secondary or atypical parkinsonian syndromes\n2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) \\>8%\n3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)\n\nAdditional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.","40 Years",{"count":157,"type":19},150,[159],"PHASE2","The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the \"leucine-rich repeat kinase 2\" (\"LRRK2\" for short) pathway based on their genetic profile. A DNA test will be used to identify the \"LRRK2-driven\" population with predicted elevation in the LRRK2 pathway.",[23,162,163,164,165],"Parkinson","Idiopathic Parkinson Disease","Early Parkinson Disease (Early PD)","Parkinson Disease, Idiopathic",[167,168,169,170,171,172,153,173,174,175,113],"Early PD","Parkinsons","Parkinsons Disease","Idiopathic Parkinsons Disease","leucine-rich repeat kinase 2","PD","LRRK2","PARK8","de novo Parkinsons disease",{"date":88,"type":30},{"date":178,"type":30},"2025-01-17",{"date":180,"type":19},"2028-06",{"name":182,"class":37},"Neuron23 Inc.",70,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":104,"sex":16,"minAge":155,"maxAge":80,"enrollmentInfo":192,"targetDuration":4,"studyType":51,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100645224","the-efficacy-and-safety-of-transcutaneous-auricular-vagus-nerve-stimulation-for-depression-in-pd-100645224","NCT07679529","The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD","Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Depressive Symptoms in Patients With Parkinson's Disease and Depression During Verbal Fluency Tasks","PD-D-taVNS","Inclusion Criteria:\n\nThis study recruited right-handed subjects from the Department of Neurology, Huai'an Second People's Hospital. The inclusion criteria for patients with PD and depression were as follows: diagnosis of idiopathic Parkinson's disease based on the clinical diagnostic criteria of the Movement Disorder Society; diagnosis of depressive disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with a Hamilton Depression Rating Scale (HAMD) score ≥ 8; stable medication regimens for Parkinson's disease for at least one month prior to enrollment; aged 40 to 80 years; and voluntary participation with written informed consent. In addition, age- and gender-matched non-depressed PD patients and healthy controls were enrolled to further compare brain functional characteristics among different groups.\n\nExclusion Criteria:\n\npresence of cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score \\\u003C 23; ongoing use of antidepressant medications; presence of contraindications related to transcutaneous auricular vagus nerve stimulation (taVNS); receipt of vagus nerve stimulation (VNS) treatment within the past month; and comorbid severe neurological, renal, cardiovascular or hepatic diseases.",{"count":193,"type":19},30,[53],"This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on Parkinson's disease patients with depression. The investigators hypothesize that taVNS will improve depression and cortical activity in Parkinson's disease patients with depression.",[23],[113,198,199],"depression","taVNS","NOT_YET_RECRUITING","2026-06-25",{"date":88,"type":30},{"date":88,"type":19},{"date":205,"type":19},"2026-08-01",{"name":207,"class":70},"The First Affiliated Hospital with Nanjing Medical University",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":216,"targetDuration":4,"studyType":51,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100538039","phase-2-a-study-of-aav2-gdnf-in-adults-with-moderate-parkinsons-disease-regenerate-pd-100538039","NCT06285643","A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)","A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease","REGENERATE-PD","Inclusion Criteria:\n\nAge\n\n1. Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics\n2. Diagnosed with Parkinson's disease in the past 4-10 years (inclusive) as defined by the following:\n\n   1. Presence of bradykinesia PLUS any of the following:\n\n      * Rigidity\n      * Rest tremor\n      * Postural instability\n   2. Presence of motor fluctuations as measured by the PD Motor Diary\n   3. Stable anti-parkinsonian medication regimen for \\>\u002F= 4 weeks prior to screening\n   4. Must demonstrate responsiveness to levodopa therapy\n\nExclusion Criteria:\n\n* Known history or current evidence of medical, genetic, or neurological conditions that may provide an alternative to idiopathic PD diagnosis\n* Presence or history of significant vascular and\u002For cardiovascular disease\n* Presence of significant cognitive impairment, poorly controlled depression\u002Fanxiety\n* Presence or history of psychosis or impulse control disorder\n* History of malignancy other than treated cutaneous squamous or basal cell carcinomas\n* Presence of clinically relevant conditions that could compromise surgical suitability and\u002For subject safety\n* Contraindication to magnetic resonance imaging and\u002For use gadolinium-based contrast agents\n* Prior history of brain surgery including, but no limited: DBS, pallidotomy focused ultrasound thalamotomy, or other experimental neurosurgical procedure\n* Chronic immunosuppressive therapy",{"count":217,"type":19},127,[159],"The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.",[23],[137],{"date":139,"type":30},{"date":224,"type":30},"2024-06-11",{"date":226,"type":19},"2028-08-31",{"name":228,"class":37},"AskBio Inc",46,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":16,"minAge":238,"maxAge":80,"enrollmentInfo":239,"targetDuration":4,"studyType":51,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":97},"100522846","apathy-in-parkinson-disease-tms-study-100522846","NCT06087926","Apathy in Parkinson Disease TMS Study","Investigation of Non-invasive Brain Stimulation for the Treatment of Apathy","PDTMSAPATHY","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson Disease.\n* At least 5 years of symptoms.\n* On dopaminergic medication for Parkinson Disease.\n* Stable on dopaminergic medication and other medications which may influence apathy (such as selective serotonin re-uptake inhibitors, stimulant medications) for at least 4 weeks prior to first study visit and remain stable throughout the study period.\n* Hospital's study-specific informed consent must be obtained.\n* Must have capacity to provide informed consent in English.\n* For female participants, confirmation that they have not had a menstrual period in over 12 months, or that they will use an effective form of contraception during the study.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Inability to perform effort task (determined during the titration session).\n* Presence of dementia (Montreal Cognitive Assessment (MoCA) score \\\u003C 21).\n* History of epilepsy or brain surgery.\n* Severe tremor or dyskinesia that would interfere with EEG (determined by the PI).\n* Patients with clinically significant medical or neurological conditions which may be an alternative cause of parkinsonism such as repeated brain injury, anti-dopaminergic medications, anoxic brain injury, or significant basal ganglia strokes.\n* Presence of other known central nervous system disease that may interfere with performance or interpretation of EEG or TMS.\n* Presence of any implanted metal devices including, but not limited to, pacemakers, deep brain stimulators, vagal nerve stimulators, bladder stimulators, or cochlear implants.\n* Presence of medical contraindications to TMS such as implanted stimulators, history of mania or bipolar disorder, history of epilepsy.","55 Years",{"count":50,"type":19},[53],"The goal of this clinical trial is to develop non-invasive brain stimulation targets for the treatment of apathy, or motivation problems, in Parkinson Disease.\n\nThe main questions the study aims to answer are:\n\n1. Does transcranial magnetic stimulation change effort task performance in Parkinson's Disease patients?\n2. Is there a link between brain signals and apathy?\n\nParticipants will\n\n* complete questionnaires and assessments\n* perform an effort task\n* have their brain activity recorded (EEG)\n* receive non-invasive brain stimulation (TMS)\n\nResearchers will compare two stimulation locations (experimental site and control site) to see if TMS of the experimental site has an effect on apathy. Participants will receive stimulation of both sites (during separate visits).",[23],[244,245],"Apathy","Motivation","2026-06-24",{"date":248,"type":30},"2026-06-26",{"date":250,"type":30},"2024-05-01",{"date":94,"type":19},{"name":253,"class":70},"University of North Carolina, Chapel Hill",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":48,"enrollmentInfo":261,"targetDuration":4,"studyType":51,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":71},"100644726","cross-system-effects-of-acute-intermittent-hypercapnia-based-interventions-in-pd-100644726","NCT07674264","Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD","A Pilot Study of Acute Intermittent Hypercapnia-Based Interventions on Upper Airway and Axial Motor Function in Parkinson's Disease","Inclusion Criteria:\n\n1. adults 40 to 75 years of age (the latter to reduce the likelihood of cardiovascular disease)\n2. diagnosis of idiopathic Parkinsonism with Hoehn and Yahr stages 2-4\n3. medically stable with physician clearance\n4. ability to ambulate at least 10 feet with\u002Fwithout assistance\n5. ability to follow directions\n6. willing to abstain from blood donation for the duration of the study\n\nExclusion Criteria:\n\n1. additional neurologic conditions\n2. severe illness or infection, including respiratory\u002Fcardiovascular\u002Flung disease, or uncontrolled hypertension\n3. inspiratory stridor\n4. pregnancy due to unknown tAIH effects on a fetus, although females of childbearing age will not be excluded\\*\n5. cigarette smoking or vaping within 5 years\n6. history of head\u002Fneck\u002Flung cancer with the exception of basal cell carcinoma\n7. is currently participating in another research study that could influence the results from this study\n8. has deep brain stimulation electrodes implanted or has a history of deep brain stimulation\n9. faints or becomes lightheaded at the sight of blood\n\n   * If a female of childbearing potential indicates there is a chance she could be pregnant, she will be provided a pregnancy test and allowed to continue in the study if negative. This is because the fetal risks associated with intermittent hypoxia are unknown.",{"count":262,"type":19},32,[53],"Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) or hypercapnic normoxia (AIHN) improves upper airway and axial motor function in Parkinsonism, and explores biomarker correlates of intervention responsiveness.",[23,266],"Parkinsonism",[268,269,270,271],"Axial function","Upper airway","Breathing","Acute Intermittent Hypercapnic Hypoxia","2026-06-23",{"date":139,"type":30},{"date":275,"type":19},"2026-06-20",{"date":277,"type":19},"2028-12-31",{"name":279,"class":70},"University of Florida",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":16,"minAge":129,"maxAge":80,"enrollmentInfo":286,"targetDuration":4,"studyType":51,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":97},"100505651","targeted-motor-learning-to-improve-gait-for-individuals-with-parkinson-disease-100505651","NCT05864157","Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease","Inclusion Criteria:\n\n* idiopathic Parkinson's disease (Hoehn and Yahr Stage 2-3)\n* self-report the ability to walk uninterrupted for 10 minutes both overground and on a treadmill without therapist assistance\n* comfortable gait speed \\> 0.4 m\u002Fs and \\\u003C 1.2 m\u002Fs\n* normal (or corrected to normal \\[i.e., hearing aid\\]) hearing\n* deficits in gait continuity (e.g., shuffling, shortened strides, freezing, festination, bradykinesia, etc) based on observational gait analysis\n* Movement Disorders Society - Unified Parkinson Disease Rating Scale (MDS-UPDRS-III) item 10 ≥1 and \\\u003C3\n* be on stable doses of orally-administered levodopa\n* age 50-80 years old\n\nExclusion Criteria:\n\n* contraindications to MRI (e.g., metal implants, claustrophobia, etc)\n* cognitive deficits (Montreal Cognitive Assessment \\[MoCA\\] \\\u003C 26)\n* concurrent Physical Therapy\n* have undergone deep brain stimulation surgery\n* cannot walk without therapist assistance\n* uncontrolled cardiorespiratory\u002Fmetabolic disease, or other neurological disorders or orthopedic injury that may affect gait.",{"count":287,"type":19},45,[53],"The purpose of this research study is to determine how training to step with a metronome on both a treadmill, as well as overground, will influence the way that people with Parkinson disease walk. Using metronomes is commonly used in clinics, but the investigators will be using a combination of slow and fast frequencies to alter the way that people walk. The use of a slower frequency metronome on the treadmill is intended to help participants take larger steps. The use of a faster frequency metronome while walking overground is intended to help participants take faster steps.This will take place over 12 training sessions. Each session will be about an hour. It will include some walking tests and pictures of the brain (using MRI) before and after training.",[23],[292,293],"Gait","Rehabilitation",{"date":201,"type":30},{"date":296,"type":30},"2023-08-16",{"date":298,"type":19},"2027-01-01",{"name":253,"class":70},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":51,"phases":310,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":97},"100603595","phase-4-boost-pd-a-naturalistic-study-on-ipx-203-for-parkinsons-disease-100603595","NCT07138560","BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease","BOOST-PD - Better On-time Observations of Motor Fluctuations Using Wearable Sensor Technology: A Naturalistic Study on IPX-203 for Parkinson's Disease","BOOST-PD","Inclusion Criteria:\n\n* \\- Participant is 40 years or older\n* Diagnosed with idiopathic Parkinson's disease and is deemed to be levodopa responsive\n* Baseline MDS-UPDRS score in OFF-state is \\> 20\n* Patient is being treated with a stable regimen of CD-LD for at least four weeks\n* The minimum most frequent levodopa dosing is 100 mg if using IR CD-LD and 195mg if using Rytary; maximum levodopa dosing per day is 1200 mg if using IR CD-LD, 1000 mg if associated with a COMT inhibitor, and 2400 mg if using Rytary\n* Participant can be on stable doses of any levodopa adjunctive medications and\u002For psychotropic medications for at least 30 days\n* Participant experiences off time estimated at 2 hours or more per day; participant can comply with the wearable kinematic device.\n\nExclusion Criteria:\n\n* \\- Participants with severe dyskinesia as defined by a score of 4 on Question 4.1 (time spent with dyskinesia) of UPDRS IV\n* Currently on device-aided therapies for advanced PD\n* Using controlled-release CD-LD apart from a single daily bedtime dose\n* Using \"on demand\" therapy unless willing to stop it during the study period\n* Have a diagnosis hypothesis of dopamine dysregulation syndrome or evidence of significant levodopa-related complications including orthostatic hypotension or psychosis\n* History of dementia or MOCA score lower than 23\n* Significant medical history might interfere significantly with study participation\n* Being enrolled in other clinical trials involving active medication interventions.",{"count":309,"type":19},22,[311],"PHASE4","The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.",[23],[315,316],"Crexont","motor fluctuations","2026-06-18",{"date":272,"type":30},{"date":320,"type":30},"2025-07-24",{"date":322,"type":19},"2027-05-15",{"name":324,"class":70},"The Cleveland Clinic",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":16,"minAge":129,"maxAge":80,"enrollmentInfo":333,"targetDuration":4,"studyType":51,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":97},"100605070","phase-2-a-trial-to-test-the-use-of-dapansutrile-an-anti-inflammatory-medication-in-people-with-parkinsons-disease-100605070","NCT07157735","A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease","Anti-inflammatory Intervention With Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind, Placebo-Controlled Phase II Trial","DAPA-PD","Inclusion Criteria:\n\nTo be included in the trial, the potential participant must:\n\n* Have given written informed consent to participate.\n* Be aged between 50 and 80 years (inclusive) at the time of the screening visit.\n* Be a fluent English speaker.\n* Have a diagnosis of clinically established early PD according to the Movement Disorder Society Criteria for Clinically Established Early Parkinson's Disease.\n* Have a disease duration of less than 5 years at the time of screening visit.\n* Have early-stage PD, defined as Hoehn and Yahr stage ≤2.\n* Be PD drug naïve or be receiving a stable dose of dopaminergic therapy for at least 3 months prior to screening visit, or between screening and baseline.\n* Have hsCRP ≥ 1 mg\u002FL on a blood test done within 2 years prior to, or at, the screening visit.\n* Have adequate organ function, as defined below (to be rechecked prior to baseline\u002Finvestigational medicinal product \\[IMP\\] initiation if \\>42 days from screening visit): Haemoglobin ≥ 110 g\u002FL; Platelet count ≥ 130 × 109\u002FL; Neutrophil count ≥ 1.5 × 109\u002FL; Renal function: estimated glomerular filtration rate (eGFR) \\>45 mL\u002Fmin\u002F1.73m2; Hepatic function: alanine aminotransferase (ALT) and bilirubin \\\u003C 1.5 times the institutional upper limit of normal; Thyroid function: thyroid stimulating hormone (TSH) within normal range; or if TSH is abnormal, free T4 within normal range; Corrected calcium ≤ institutional upper limit of normal; Alkaline phosphatase (ALP) \\\u003C 1.5 times the institutional upper limit of normal\n\nExclusion Criteria:\n\nThe presence of any of the following will preclude inclusion:\n\n* Low affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.\n* Any use of immunomodulatory drugs or biologic agents (such as azathioprine, mycophenolate, methotrexate, ciclosporin, cyclophosphamide etc.) within 12 months prior to screening visit, or between screening and baseline.\n* Any previous use of rituximab or alemtuzumab at any time.\n* Treatment with oral corticosteroids for greater than 2 weeks within 12 months prior to screening visit, or any oral or injected steroid use within 3 months prior to screening visit, or between screening and baseline.\n* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) - including aspirin \\> 75 mg, naproxen, ibuprofen and meloxicam - on more than 2 days per week.\n* Clinically significant inflammatory or autoimmune disease.\n* Chronic or latent infection.\n* Severe infection requiring the use of parenteral antimicrobial agents within 2 months prior to screening visit, or between screening and baseline.\n* Skin, solid organ or haematological malignancy which is active\\* at screening, or between screening and baseline (\\*defined as cancer which is under active management, with the exception of low-grade malignancy under observation of hormonal treatment).\n* The inability to take or swallow oral medication.\n* Parkinson's Disease Dementia according to Movement Disorder Society (MDS) PD Dementia criteria.\n* A known genetic mutation associated with PD.\n* A positive test for human immunodeficiency virus (HIV), hepatitis B (HBV)\u002FC (HCV) or syphilis.\n* Chronic liver disease.\n* Any concurrent medical or psychiatric condition or disease that is likely to interfere with the trial procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this trial.\n* Women of childbearing potential - female participants must be surgically sterile or be post-menopausal. (A post-menopausal state is defined as no menses for 12 months without an alternative medical cause).\n* Male participants must be surgically sterile or must agree to use effective contraception during the period of therapy and for 6 months after the last dose of the trial treatment.\n* Known hypersensitivity to dapansutrile or its excipients.\n* Received an investigational drug or used an invasive investigational medical device within 12 weeks before the screening assessment, or is currently enrolled in another interventional investigational trial. Participants currently enrolled in other observational studies may be recruited.\n* Contraindications to PET-magnetic resonance imaging (MRI) scanning including metal implants, claustrophobia or inability to lie flat for 90 minutes.\n* Concomitant treatment with any medications that could interfere with \\[18F\\]-DPA714 binding (e.g., certain benzodiazepines), with the exception of medications which can be safely withheld for an appropriate washout period prior to imaging at the investigator's discretion.\n* Current use of any drugs of abuse or average alcohol intake of \\>21units per week over the last 3 months.\n* Any other significant disease, disability or investigation result which, in the opinion of the Chief Investigator (CI), may either put the participant at risk, or may influence the result of the trial, or the participant's ability to participate in the trial.",{"count":334,"type":19},36,[159],"In Parkinson's disease (PD), there is inflammation in the brain, the gut and the blood, which is thought to contribute to the development and progression of the disease. The Nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is a complex of proteins which plays a critical role in mediating inflammation, and there is growing evidence from laboratory research that the inflammasome plays a role in Parkinson's disease.\n\nDapansutrile is a new drug which has a highly specific effect on the NLRP3 inflammasome. In animal models, dapansutrile can protect against inflammation in the brain and prevent loss of dopamine cells. Initial 'in human' studies have indicated that this drug can effectively reduce inflammation without causing significant side effects.\n\nThe goal of this clinical trial is to test whether dapansutrile might be a useful treatment for Parkinson's disease. The main questions it aims to answer are:\n\n1. is dapansutrile safe and well-tolerated in people with Parkinson's?\n2. does dapansutrile reduce inflammation in the brain, cerebrospinal fluid (CSF) and blood? Changes in clinical symptoms will also be measured over the course of the trial.\n\nResearchers will compare dapansutrile to a placebo (a look-alike substance that contains no drug) to see whether it is safe and what effects it has on inflammation and on clinical symptoms.\n\nParticipants will be asked to take dapansutrile or a placebo every day for 6 months. Following this, all participants will be given the option to take dapansutrile every day for an additional 6 months. Participants will visit the study centre regularly throughout the trial for check-ups and blood tests. They will have a brain scan before starting treatment and again after 5-6 months. They will also be asked to have a lumbar puncture at the beginning of the trial, after 6 months of treatment and after 12 months of treatment.",[23],[339,340,341,342,343],"Dapansutrile","Neurodegeneration","Neuroinflammation","Inflammation","NLRP3 inflammasome","2026-06-12",{"date":346,"type":30},"2026-06-16",{"date":348,"type":30},"2026-02-02",{"date":180,"type":19},{"name":351,"class":70},"Cambridge University Hospitals NHS Foundation Trust",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":16,"minAge":359,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":51,"phases":362,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100631800","efficacy-of-a-prediction-model-based-algorithm-to-prevent-drug-induced-impulse-control-disorders-in-parkinsons-disease-100631800","NCT07505394","Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease","PREVENT-ICD","Inclusion Criteria:\n\n* Male and female ≥ 18 years old\n* Diagnosis of PD according to the 2015 Movement Disorders Society criteria (Postuma et al., Mov Disord. 2015), with bradykinesia AND at least ONE of the following: muscular rigidity, or resting tremor; with no other suspected cause of parkinsonism\n* Disease duration below 6 years included\n* No ongoing clinically significant (Mild or above) ICDRBs (any ASBPD part IV subscores in any of the items 3 to 5 and 7 to 10 each \\\u003C2)\n* Patients currently treated with DA for at least 2 months and without current planned or known reason for stopping DA over the next 3 years\n\nExclusion Criteria:\n\n* Atypical or secondary parkinsonism such as supranuclear palsy, multisystem atrophy or drug-induced parkinsonism, etc...\n\n  * Patients with a cognitive or psychiatric disorder preventing patient's participation as per investigator's judgement\n  * Not willing to participate to the Clinical Investigation or to sign the consent\n  * Pregnant or lactating woman, or WOCBP tested positive in \\\u003Cserum or urine\\> pregnancy test\n  * Participation in investigational drug trials within 30 days prior to screening or within 5 half-life of investigational product whatever the longest\n  * Participant not affiliated or beneficiary of a French social security system","18 Years",{"count":361,"type":19},528,[53],"Impulse control disorders and related behaviors (ICDRBs) are characterized by pathological gambling, compulsive shopping or eating, and hypersexuality, but other related behaviors have been described, e.g. hobbyism, and punding. ICDRBs are frequent in Parkinson's Disease (PD), affecting up to 50% of the patients after 5 years with major medical, social, and legal impact, with life changing consequences for patients and caregivers. The main risk factor is dopaminergic therapy, particularly the cumulative dose of dopamine agonists (DA). On the other hand, the dopaminergic therapy is necessary to control motor symptoms, and DA have demonstrated efficacy in delaying motor complications occurring in PD. Ideally, dopaminergic therapy would have to be adjusted to the individual risk of developing ICRDBs to maximize the benefit\u002Frisk ratio of each drug. However, despite several clinical risk factors associated with the risk of ICDRBs (in addition to the dopaminergic therapy), it is still not possible to predict their risk at the individual level, and not every patient treated with dopaminergic medications will develop ICDRBs. A machine learning algorithm to predict ICDRBs, based on clinical data, validated by cross-validation on independent replication cohorts has been developed. The PREVENT-ICD study proposes to test the efficacy of a new application, ICD-Shield, based on an algorithm to predict and prevent ICDs,in a multicenter randomized controlled trial to prevent ICDRBs in PD patients by proposing to the clinician treatment adjustment according to the risk predicted by the algorithm, as compared to the standard of care (SoC)",[23,365],"Impulse Control Disorder",[367,368,369],"Agonists, Dopamine","Impulse Control Disorders","ICD SHIELD app","2026-06-10",{"date":344,"type":30},{"date":88,"type":19},{"date":374,"type":19},"2031-06-01",{"name":376,"class":70},"Assistance Publique - Hôpitaux de Paris",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":51,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":97},"100624405","neurophysiology-of-reward-signaling-in-parkinsons-disease-100624405","NCT07409207","Neurophysiology of Reward Signaling in Parkinson's Disease","Inclusion Criteria:\n\n* Scheduled to undergo deep brain stimulation surgery under local anesthesia at Vanderbilt University Medical Center\n* Planned clinical electrode trajectory that contacts caudate\n* Age greater than or equal to 40\n* Diagnosis of Parkinson's disease or other movement disorder\n* Able to participate in intraoperative testing\n* English speaking\n\nExclusion Criteria:\n\n* Age less than 40\n* Not able to participate in intraoperative testing (for example unable to comprehend instructions or follow directions)",{"count":384,"type":19},75,[53],"The goal of this study is to learn more about the brain activity underlying Parkinson's disease risk taking and reward seeking behaviors. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease.",[23],[389],"Deep Brain Stimulation",{"date":344,"type":30},{"date":392,"type":30},"2024-09-01",{"date":394,"type":19},"2029-09-30",{"name":396,"class":70},"Vanderbilt University Medical Center",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":404,"targetDuration":406,"studyType":20,"phases":4,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":417},"100558630","radiofrequency-rf-ablation-prospective-outcomes-study-for-central-nervous-system---rapid-for-cns-100558630","NCT06553625","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)\n* Signed a valid, IRB\u002FEC\u002FREB-approved informed consent form\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Directions for Use (DFU)\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":405,"type":19},200,"24 Months","The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.",[23,25,24,409],"Movement Disorders",{"date":411,"type":30},"2026-06-11",{"date":413,"type":30},"2024-01-29",{"date":415,"type":19},"2035-12",{"name":36,"class":37},4,{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":51,"phases":426,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":97},"100417461","corticostriatal-contributions-to-parkinsons-disease-cognitive-impairment-100417461","NCT04715984","Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment","Corticostriatal Neurophysiology in Parkinson's Disease Cognitive Impairment","Inclusion criteria:\n\n* Scheduled to undergo deep brain stimulation surgery under local anesthesia at Vanderbilt University Medical Center\n* Planned clinical electrode trajectory that contacts caudate\n* Age greater than or equal to 40\n* Diagnosis of Parkinson's disease\n* Able to participate in intraoperative testing\n* English speaking\n\nExclusion criteria:\n\n* Age less than 40\n* Not able to participate in intraoperative testing (for example unable to comprehend instructions or follow directions)\n* Movement disorder other than Parkinson's disease",{"count":384,"type":19},[53],"The goal of this study is to learn more about the brain activity underlying Parkinson's disease cognitive impairment. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease.",[23],[389],{"date":344,"type":30},{"date":432,"type":30},"2021-06-02",{"date":434,"type":19},"2029-08",{"name":396,"class":70},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":104,"sex":16,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":464},"100399177","ppmi-clinical---establishing-a-deeply-phenotyped-pd-cohort-100399177","NCT04477785","PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort","The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort","PPMI","7.1 Healthy Controls (HC) Note: Active Healthy controls previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.1.1 Inclusion Criteria (HC)\n\n1. Male or female age 57 years or older at Screening visit.\n2. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n3. Confirmation that participant is eligible based on Screening SPECT imaging.\n4. Able to provide informed consent.\n5. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.1.2 Exclusion Criteria (HC)\n\n1. First degree relative with PD (i.e., biologic parent, sibling, child).\n2. Current or active clinically significant neurological disorder (in the opinion of the Investigator).\n3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n4. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n5. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.\n6. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n7. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n8. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.2 Parkinson's Disease (PD) Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.2.1 Inclusion Criteria (PD)\n\n1. Male or female age 30 years or older at Screening Visit.\n2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit.\n3. Not expected to require PD medication within at least 6 months from Baseline.\n4. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n5. Hoehn and Yahr stage I or II at Baseline.\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.2.2 Exclusion Criteria (PD)\n\n1. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n2. Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline visit.\n3. Has taken levodopa or dopamine agonists prior to Baseline visit for more than a total of 90 days.\n4. Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).\n5. A clinical diagnosis of dementia as determined by the investigator.\n6. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n7. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n8. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.\n9. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n10. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n11. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.3 Parkinson's Disease (PD) with LRRK2 or GBA variant Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.3.1 Inclusion Criteria (PD ¬- LRRK2 or GBA)\n\n1. Male or female age 30 years or older at Screening Visit.\n2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit.\n3. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n4. Hoehn and Yahr stage I or II at Baseline.\n5. Confirmation of causative LRRK2 or GBA (willingness to undergo genetic testing as part of genetic screening and be informed of genetic testing results, or approved documentation of prior genetic testing results).\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.3.2 Exclusion Criteria (PD - LRRK2 or GBA)\n\n1. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n2. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n3. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n5. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.4 Parkinson's Disease (PD) with SNCA or rare genetic variant Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.4.1 Inclusion Criteria (PD - SNCA or rare genetic variant (such as Parkin or Pink1))\n\n1. Male or female age 30 years or older at Screening Visit.\n2. Parkinson's disease diagnosis at Screening Visit.\n3. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n4. Hoehn and Yahr stage I, II, or III at Baseline.\n5. Confirmation of causative SNCA or rare genetic variant (such as Parkin or Pink1) (willingness to undergo genetic testing as part of genetic screening and be informed of genetic testing results, or approved documentation of prior genetic testing results).\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.4.2 Exclusion Criteria (PD - SNCA or rare genetic variant (such as Parkin or Pink1))\n\n1. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n2. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n3. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n5. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.5 Prodromal Note: Active Prodromal participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\nThe specific predictive eligibility criteria for participants recruited through PPMI Remote to advance to PPMI Clinical will be iteratively optimized based on data collected from these studies.\n\n7.5.1 Inclusion criteria (Prodromal)\n\nFor Screening:\n\n1. Confirmation that participant is eligible based on centrally determined predictive criteria including the University of Pennsylvania Smell Identification Test (UPSIT).\n\n   * For participants in PPMI Remote, referral to the clinical site confirms predictive eligibility.\n   * For participants identified by the clinical site, predictive criteria are based on generalized risk such as first degree biologic relative, known risk of PD including RBD, or known genetic variants associated with PD risk.\n\n   Additionally, confirmation of UPSIT eligibility during the Screening visit prior to SPECT Imaging.\n2. Male or female age 60 years or older (except age 30 years or older for SNCA, or rare genetic variants (such as Parkin or Pink1) participants).\n3. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n4. Able to provide informed consent.\n5. Either is male, or is female and meets additional criteria below, as applicable:\n\n   • Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n   For continuation to Baseline visit and ongoing follow-up:\n6. Confirmation that participant is eligible based on \\*Screening SPECT imaging.\n\n   * Screening SPECT Imaging eligibility:\n\nBased on the results of the SPECT imaging test, Prodromal participants eligible to continue their participation in PPMI Clinical will be asked to return for their PPMI Clinical baseline visit. Neither the participant nor the site investigator will be made aware of the participant's DAT status during the study.\n\n* It is anticipated that approximately 6,000 participants will complete a screening visit to undergo DAT imaging. Approximately 2,000 participants will be eligible to continue their participation in PPMI Clinical (those not eligible to proceed will remain in PPMI Remote, as applicable).\n* All participants with DAT deficit will be eligible to continue their participation in PPMI Clinical. It is estimated that about 75% of eligible participants will have a DAT deficit (defined by a hybrid of visual assessment and quantitative striatal specific binding analysis).\n* Some participants without DAT deficit will also be eligible to continue their participation in PPMI Clinical. These participants will be chosen based on DAT binding that is reduced from age expected but it not outside the normal range and\u002For from individuals with high-risk of PD including RBD, LRRK2, GBA, SNCA, or rare genetic variants (such as Parkin or Pink1) that do not demonstrate DAT deficit. It is estimated that about 25% of eligible participants will not have a DAT deficit.\n* It is anticipated that approximately 30% of the PPMI Clinical prodromal participants with DAT deficit will phenoconvert to motor parkinsonism during a 3 to 5-year follow-up.\n\n7.5.2 Exclusion Criteria (Prodromal)\n\n1. Clinical diagnosis of PD at screening, other parkinsonism, or dementia.\n2. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Baseline Visit.\n3. Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n4. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n5. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n6. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n7. Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline visit. except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n8. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.","30 Years",{"count":446,"type":19},4500,"The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls.\n\nThe overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.",[23],[162,450,451,452,453,454,455,456],"Bio-markers","Neurodegenerative disorder","Imaging","Prodromal","Genetics","At Risk","Loss of Smell",{"date":344,"type":30},{"date":459,"type":30},"2020-07-01",{"date":461,"type":19},"2033-12",{"name":463,"class":70},"Michael J. Fox Foundation for Parkinson's Research",50,{"id":466,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":468,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":472,"locationsCount":38},"100336760",{"count":18,"type":19},[23,24,25],{"date":344,"type":30},{"date":32,"type":30},{"date":34,"type":19},{"name":36,"class":37},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":51,"phases":482,"briefSummary":483,"conditions":484,"keywords":487,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":501,"locationsCount":4},"100643119","telerehabilitation-versus-face-to-face-lsvt-big-in-individuals-with-parkinson-disease-100643119","NCT07630792","Telerehabilitation Versus Face-to-Face LSVT BIG in Individuals With Parkinson Disease","The Effects of Telerehabilitation and Face-to-Face LSVT BIG Method on Motor and Non-Motor Symptoms in Individuals With Parkinson Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease\n* Hoehn and Yahr stage 1-3\n* Montreal Cognitive Assessment (MoCA) score ≥ 21\n* Ability to use a smartphone, tablet, or computer\n* Access to internet connection and basic digital literacy\n* Participation in activities outside the home at least 3 days per week\n\nExclusion Criteria:\n\n* Diagnosis of a neurological condition other than idiopathic Parkinson's disease\n* Change in antiparkinsonian medication regimen during the study period\n* History of deep brain stimulation\n* Visual or hearing impairment that would prevent participation in treatment or assessments\n* Severe cardiovascular, orthopedic, pulmonary, or systemic comorbidity contraindicating exercise\n* Diagnosis of severe depression, psychotic disorder, or uncontrolled psychiatric illness\n* Participation in another structured physiotherapy or rehabilitation program for\n* Parkinson's disease within the last three months",{"count":481,"type":19},40,[53],"This prospective, randomized controlled trial will enroll 40 individuals with idiopathic PD (Hoehn \\& Yahr stages 1-3, MoCA ≥21). Participants will be randomly assigned in a 1:1 ratio to either a telerehabilitation LSVT BIG group or a face-to-face LSVT BIG group, with randomization stratified by Hoehn \\& Yahr stage using a computer-based block randomization system. Both groups will receive the standard LSVT BIG® protocol consisting of 16 sessions over four weeks (4 days\u002Fweek, 1 hour\u002Fsession). Treatment content will include maximal daily exercises, functional component tasks, \"big\" gait training, and individually tailored hierarchy tasks. The telerehabilitation group will receive all sessions via synchronous video conferencing under physiotherapist supervision, while the face-to-face group will receive sessions in a clinical setting. Both groups will be assigned home exercise programs in accordance with the LSVT BIG® protocol, and treatment adherence will be monitored throughout the study.\n\nOutcomes will be assessed at baseline, after 4 weeks of treatment, and at 6-month follow-up. Primary outcomes include postural stability and fall risk assessed with the Biodex Balance System (anterior-posterior stability index, mediolateral stability index, general stability index, fall risk index, limits of stability) and motor and non-motor symptom severity assessed with the MDS-UPDRS (Parts I, II, and III). Secondary outcomes include dynamic balance (Mini-BESTest), functional mobility (Timed Up and Go Test, 10-Meter Walk Test), quality of life (PDQ-39), depression (Beck Depression Inventory), sleep quality (Parkinson's Disease Sleep Scale), fatigue (Parkinson Fatigue Scale), cognitive function (MoCA), and treatment satisfaction (Global Rating of Change Scale).",[485,486,23],"PARKINSON DISEASE (Disorder)","Parkinson Disease (PD), Postural Balance",[23,488,489,490,491,492,493,494,495],"LSVT BIG","Telerehabilitation","Motor Symptoms","Non-Motor Symptoms","Balance","Neuroplasticity","Randomized Controlled Trial","Physical Therapy","2026-06-09",{"date":411,"type":30},{"date":275,"type":19},{"date":500,"type":19},"2028-06-30",{"name":502,"class":70},"Bezmialem Vakif University",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":51,"phases":512,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":97},"100589118","effect-of-training-and-use-of-cane-on-gait-in-individuals-with-parkinsons-disease-100589118","NCT06950255","Effect of Training and Use of Cane on Gait in Individuals With Parkinson's Disease","Effect of a 3-week Program of Cane Training and Use on Gait of Individuals With Parkinson's Disease: Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of idiopathic PD confirmed by a neurologist\n* classification between stages II to IV of the modified Hoehn \\& Yahr Scale (HY)\n* use of anti-parkinsonian medication with stable pharmacological therapy for at least 6 months\n* ability to walk independently in a 14-meter corridor with a walking speed ≤ 1.1 m\u002Fs\n* ability to use a single-point cane during walking correctly and safely, and not being regular users of any type of assistive device since the diagnosis of PD.\n\nExclusion Criteria:\n\n* cognitive impairment, assessed by the Mini Mental State Examination\n* use deep brain stimulation,\n* had any other neurological, cardiopulmonary or musculoskeletal condition that may compromise the tests performance",{"count":511,"type":19},26,[53],"Introduction: Although individuals with Parkinson's disease (PD) commonly use assistive devices, the effects of these devices on gait remain poorly understood. Furthermore, previous studies on this topic only investigated the immediate effects of device usage, and the investigated outcomes were predominately performance-based neglecting participant-centered outcomes.\n\nObjective: To investigate the effect of cane training and use on gait speed (primary outcome), gait confidence, cadence, step length, functional mobility, freezing of gait, fear of falls and satisfaction with the use of a cane (secondary outcomes) in individuals with PD.\n\nMethods: A double-blind, randomized controlled trial with intention-to-treat and per-protocol analysis will be carried out. A total of 26 individuals with PD will be recruited based on the following inclusion criteria: age ≥ 40 years, diagnosis of idiopathic PD, classification between stages II to IV on the modified Hoehn \\& Yahr Scale, stable use of anti-parkinsonian pharmacological therapy, ability to walk independently with a walking speed ≤ 1.1 m\u002Fs (defined to screen individuals with gait impairments), and ability to use a single-point cane during walking without regular use of any type of assistive device since the diagnosis of PD. Participant will be randomly divided into two groups that will receive: (1) cane training and use (experimental group) or (2) global stretches and health education (time and attention-controlled group). The intervention will be provided in four sessions lasting 40 minutes each, spaced over 15 to 22 days. Additionally, individuals will be instructed to use a cane (experimental group) or perform stretching exercises (time and attention-controlled group) daily, starting from the first day of training. Assessments will be conducted at the beginning of the study (week 0), post-intervention (after the 3-week intervention), and one month after the cessation of the intervention (8-week follow-up). The primary outcomes is gait speed. Secondary outcomes include gait confidence, cadence, step length, functional mobility, freezing of gait, fear of falls, and satisfaction with the use of a cane. Between-group differences will be measured using a two-way repeated measures ANOVA, considering baseline, post-intervention, and follow-up assessments, following both intention-to-treat and per-protocol approaches (α=0.05).\n\nConclusions: The results of the present study will provide information about the effects of cane training and use on the gait of individuals with PD who will have the opportunity to use the cane in their real-life context.",[23],[516,517,518,110],"assistive device","canes","mobility",{"date":411,"type":30},{"date":521,"type":30},"2025-05-01",{"date":523,"type":19},"2026-09-30",{"name":525,"class":70},"Federal University of Minas Gerais",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":359,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":550},"100193894","natural-history-study-of-synucleinopathies-100193894","NCT01799915","Natural History Study of Synucleinopathies","Inclusion Criteria:\n\n1. Both male and female patients will be included\n2. Aged 18 or over\n3. Referred to any of the participating consortium sites with orthostatic intolerance, defined as symptoms of dizziness or lightheadedness in the standing position that disappear when supine.\n\nExclusion Criteria:\n\n1. Diabetes according to the American Diabetes Association criteria\n2. Congestive heart failure\n3. Lupus or other collagen vascular disease\n4. Systemic illness thought to be responsible for the orthostatic intolerance\n5. Drug-induced orthostatic hypotension (i.e., the use of alpha-blockers, diuretics, tricyclic antidepressants or others thought by the investigator to play an important role in the patient's orthostatic hypotension)\n6. Isolated vasovagal syncope\n7. Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.",{"count":533,"type":19},800,"Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control of movement or cognition. Patients with synucleinopathies and signs of CNS-deficits are frequently diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA).\n\nHowever, accumulation of alpha-synuclein and death of nerve cells can also begin outside the brain in the autonomic nerves. In such cases, syncucleinopathies present first with symptoms of autonomic impairment (unexplained constipation, urinary difficulties, and sexual dysfunction). In rare cases, hypotension on standing (a disorder known as orthostatic hypotension) may be the only clinical finding. This \"pre-motor\" autonomic stage suggests that the disease process may not yet have spread to the brain.\n\nAfter a variable period of time, but usually within 5-years, most patients with abnormally low blood pressure on standing develop cognitive or motor abnormalities. This stepwise evolution indicates that the disease spreads from the body to the brain. Another indication of this spread is that acting out dreams (i.e., REM sleep behavior disorder, RBD) a problem that occurs when the lower part of the brain is affected, may also be the first noticeable sign of Parkinson disease.\n\nThe purpose of this study is to document the clinical features and biological markers of patients with synucleinopathies and better understand how these disorders evolve over time. The study will involve following patients diagnosed with a synucleinopathy (PD\u002FDLB and MSA) and those believed to be in the \"pre-motor\" stage (with isolated autonomic impairment and\u002For RBD). Through a careful series of follow-up visits to participating Centers, we will focus on finding biological clues that predict which patients will develop motor\u002Fcognitive problems and which ones have the resilience to keep the disease at bay preventing spread to the brain. We will also define the natural history of MSA - the most aggressive of the synucleinopathies.",[536,537,538,539,23,540,541,542],"Patients With Synucleinopathies","Neurogenic Orthostatic Hypotension","Pure Autonomic Failure","REM Sleep Behavior Disorder","Dementia With Lewy Bodies","Multiple System Atrophy","Shy-Drager Disease",{"date":370,"type":30},{"date":545,"type":30},"2011-06",{"date":547,"type":19},"2026-12-30",{"name":549,"class":70},"NYU Langone Health",8,{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":173,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":97},"100642321","striatal-and-extra-striatal-cholinergic-terminal-density-in-lrrk2-pd-mutation-100642321","NCT07642908","Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation","Inclusion Criteria:\n\n1. Male or Female, age 45 years and over.\n2. Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992).\n3. Presence of LRRK2 mutation as confirmed by referral from UM Movement Disorders clinic, medical record review, or participation in the PDGENEration study.\n\nExclusion Criteria:\n\n1. Evidence of atypical parkinsonism.\n2. Contra-indications to MR imaging including but not limited to pacemakers, aneurysm clips, intraocular metal, cochlear implant, or severe claustrophobia.\n3. Evidence of large vessel stroke or mass lesion on MRI.\n4. Regular use of typical anti-cholinergic drugs or cholinesterase inhibitors.\n5. History of deep brain stimulation surgery.\n6. Pregnant or nursing.\n7. Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.\n8. Cognitive impairment that results in the inability to give consent, as demonstrated by the Decision Making Capacity Tool.\n9. Any other condition or criterion that would preclude safe and meaningful participation in the study.",{"count":558,"type":19},15,"This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.",[23],[134,562,173,563],"LRRK","functional neuroimaging","2026-06-08",{"date":411,"type":30},{"date":567,"type":30},"2025-09-18",{"date":569,"type":19},"2026-09-17",{"name":571,"class":70},"University of Michigan",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":16,"minAge":359,"maxAge":80,"enrollmentInfo":579,"targetDuration":4,"studyType":51,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":97},"100633383","the-effect-of-eye-exercises-in-parkinsons-disease-100633383","NCT07525973","The Effect of Eye Exercises in Parkinson's Disease","The Effect of Eye Exercises on Physical Function, Balance, and Fall Risk in Patients With Parkinson's Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\nAged 18 years and older Clinically diagnosed idiopathic Parkinson's disease Hoehn and Yahr stage 1-3 Stable antiparkinsonian medication regimen Able to stand unaided and walk with or without an assistive device Able to provide written informed consent Able to attend supervised in-center exercise sessions Able to follow simple exercise instructions\n\nExclusion Criteria:\n\nSevere cognitive impairment Unstable cardiovascular, orthopedic, or neurologic conditions that interfere with safe participation Active infection or acute medical illness Hemodynamic instability Severe visual impairment or other sensory impairment that prevents participation Recent myocardial infarction or stroke Unstable or changing antiparkinsonian medication regimen Any other condition that, in the judgment of the study physician, makes participation unsafe",{"count":580,"type":19},34,[53],"Parkinson's disease is commonly associated with impaired gait, postural instability, reduced physical function, and increased concern about falling, all of which contribute substantially to disability and reduced quality of life. Exercise-based rehabilitation is increasingly recommended as a core non-pharmacological strategy for improving mobility and balance in people with Parkinson's disease. In parallel, recent clinical and neurorehabilitation research suggests that eye-movement and gaze-stabilization training may influence postural control, visuomotor integration, and movement performance in neurological disorders, including Parkinson's disease. This randomized controlled trial will evaluate whether a supervised in-center eye-exercise program can improve physical function, balance, and fall-related concern in patients with Parkinson's disease.",[23],[585,586,492,587,588,589,292,590],"Parkinson disease","Eye exercises","Fall risk","Physical function","Functional mobility","Postural stability","2026-06-07",{"date":496,"type":30},{"date":594,"type":30},"2026-05-01",{"date":596,"type":19},"2026-09-01",{"name":598,"class":70},"Pardis Specialized Wellness Institute",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":104,"sex":16,"minAge":129,"maxAge":80,"enrollmentInfo":606,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":97},"100643379","upper-extremity-skills-trunk-control-and-body-awareness-in-parkinsons-disease-100643379","NCT07639463","Upper Extremity Skills, Trunk Control, and Body Awareness in Parkinson's Disease","Investigation of Upper Extremity Skills, Trunk Control, and Body Awareness in Individuals With Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease\n* Age between 50 and 80 years\n* Montreal Cognitive Assessment (MoCA) score ≥21\n* Modified Hoehn and Yahr Stage 2-3\n* Stable medication regimen with no medication or dosage changes within the previous month\n* Ability to understand and follow instructions\n* Voluntary agreement to participate\n\nExclusion Criteria:\n\n* Presence of another chronic neurological disorder\n* Orthopedic or rheumatologic conditions limiting upper extremity movement\n* Previous upper extremity or trunk surgery\n* Severe tremor or dyskinesia preventing participation in assessments\n* Significant visual or communication impairments interfering with testing",{"count":607,"type":19},118,"Parkinson's disease is associated with impairments in upper extremity function, postural control, and sensory-motor processing that may negatively affect daily activities and quality of life. While upper extremity dysfunction has been extensively investigated, the potential contributions of trunk control and body awareness have received less attention. This cross-sectional observational study aims to compare upper extremity skills, trunk control, and body awareness between individuals with Parkinson's disease and healthy adults, and to examine the relationships among these variables within the Parkinson's disease group. The findings may improve understanding of factors associated with upper extremity performance and support the development of more comprehensive rehabilitation approaches for individuals with Parkinson's disease.",[23],[611,612,134,613],"Functionality","Body","Upper Extremity","2026-06-06",{"date":370,"type":30},{"date":617,"type":19},"2026-06-15",{"date":619,"type":19},"2026-10-10",{"name":621,"class":70},"Baskent University"]